SCHEMBL324620

SCHEMBL324620

O=C(OCc1ccncn1)N1C=Cc2ccccc2C1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 4/20 0.38
GRIN2B Q13224 2/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
HDAC3 O15379 1/20 0.34
GABRA1 P14867 2/20 0.33
GABRG2 P18507 2/20 0.33
GABRB3 P28472 2/20 0.33
GABRA5 P31644 2/20 0.33
GABRA3 P34903 2/20 0.33
GABRA2 P47869 2/20 0.33
GRM5 P41594 1/20 0.33
SYK P43405 1/20 0.32
AURKB Q96GD4 1/20 0.32
INCENP Q9NQS7 1/20 0.32
P2RX4 Q99571 1/20 0.32
NPC1 O15118 2/20 0.31
RAB9A P51151 2/20 0.31
LMNA P02545 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15057230 0.87 NPC1 (0.43) CYP3A4CYP2D6CYP2C9HDAC3SYK
SCHEMBL324696 0.84 PTGDR2 (0.36) GRIN2BCYP3A4CYP2D6CYP2C9HDAC3
SCHEMBL325711 0.80 P2RX4 (0.39) GRIN2BCYP3A4CYP2D6CYP2C9HDAC3
SCHEMBL324299 0.78 P2RX4 (0.52) P2RX4NPC1RAB9ASMN1; SMN2HRH1
SCHEMBL324887 0.77 CYP3A4 (0.36) GRIN2BCYP3A4CYP2D6HDAC3GRM5
SCHEMBL325045 0.77 NAMPT (0.38) NAMPTHDAC3P2RX4NPC1LMNA
SCHEMBL15056293 0.77 DPP4 (0.41) CYP3A4HDAC3GABRA1GABRG2GABRB3
SCHEMBL324037 0.76 MAPT (0.40) GABRA1GABRA5NPC1RAB9ALMNA
SCHEMBL15056964 0.76 HDAC3 (0.41) NAMPTGRIN2BHDAC3RAB9ALMNA
SCHEMBL29493251 0.76 HDAC3 (0.41) NAMPTGRIN2BHDAC3RAB9ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2590944-A1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS Actelion Pharmaceuticals Ltd. (CH) 2013-05-15 EP disclosed
US-20130109685-A1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS ACTELION PHARMACEUTICALS LTD. (CH) 2013-05-02 US disclosed
WO-2012004722-A1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS ACTELION PHARMACEUTICALS LTD (CH) 2012-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130109685-A1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS PTGER1, PTGDR, PTGDR2 NAMPT 2828/4885GRIN2B 1330/4885CYP3A4 434/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.